Rivoceranib - LSK Biopharma

Drug Profile

Rivoceranib - LSK Biopharma

Alternative Names: AiTan; Apatinib; Apatinib mesylate; YN-968-D1

Latest Information Update: 25 Jun 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Advenchen Laboratories LLC
  • Developer Bukwang Pharmaceutical; Fudan University Shanghai Cancer Center; Jiangsu Hengrui Medicine Co.; LSK Biopharma; Peking University People's Hospital; The Affiliated Hospital of the Chinese Academy of Military Medical Science
  • Class Amides; Antineoplastics; Pyridines; Small molecules
  • Mechanism of Action Angiogenesis inhibitors; Vascular endothelial growth factor receptor-2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Gastric cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Gastric cancer
  • Phase III Hepatocellular carcinoma; Non-small cell lung cancer
  • Phase II Breast cancer; Colorectal cancer; Osteosarcoma; Solid tumours
  • Phase I/II Cancer
  • Phase I Fallopian tube cancer; Ovarian cancer; Peritoneal cancer

Most Recent Events

  • 19 Jun 2018 Phase-I/II clinical trials in Cancer (Second-line therapy or greater, Combination therapy, Late-stage disease) in USA (PO) (NCT03407976)
  • 12 Jun 2018 Efficacy and adverse events data from a phase II study in Metastatic colorectal cancer presented at the 54th Annual Meeting of the American Society of Clinical Oncology (ASCO-2018)
  • 01 Jun 2018 Safety and efficacy data from a phase I/II trial in Solid tumours presented at the 54th Annual Meeting of the American Society of Clinical Oncology (ASCO-2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top